# Anti-platelet + Pembro for H&N Tumors

> **NCT03245489** · PHASE1 · COMPLETED · sponsor: **Medical University of South Carolina** · enrollment: 20 (actual)

## Conditions studied

- Head and Neck Cancer

## Interventions

- **DRUG:** Pembrolizumab
- **DRUG:** Clopidogrel
- **DRUG:** acetylsalicylic acid

## Key facts

- **NCT ID:** NCT03245489
- **Lead sponsor:** Medical University of South Carolina
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-03-06
- **Primary completion:** 2023-11-20
- **Final completion:** 2024-11-20
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2025-01-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03245489

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03245489, "Anti-platelet + Pembro for H&N Tumors". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03245489. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*